Ipamorelin

Selective ghrelin receptor agonist (GH secretagogue)

A pentapeptide GH secretagogue selective for the ghrelin receptor, so it raises growth hormone without the cortisol and prolactin rise seen with older secretagogues. Clinical development was discontinued.

ALSO KNOWN AS NNC 26-0161

REGULATORY STATUS · RESEARCH COMPOUND

Research compound — not approved for human use. Compounds in this category have not been approved for human use; availability is typically restricted to laboratory research.

§ EVIDENCE BASE

PUBLICATIONS

indexed in PubMed

REGISTERED TRIALS

listing it as an intervention

PHASE 2–4 TRIALS

reached later-stage testing

MECHANISMSelective ghrelin receptor agonist (GH secretagogue)

CATEGORYGrowth Hormone

EVIDENCE GRADEC — Mostly preclinical

STATUSResearch compound — not approved for human use

TYPICAL RECONSTITUTION5 mg vial + 2.5 mL BAC water

ROUTESubcutaneous — abdomen

COUNTS RETRIEVED2026-07-23 · re-run the PubMed query

§ DOCUMENTED DOSING

Standard200–300 mcg, 1–3× daily

Best timingbefore bed and/or post-workout, on an empty stomach

Cycle12+ weeks

Ranges compiled from published protocols, not a clinical guideline. Convert a dose into syringe units with the dosage calculator.

§ RELATED COMPOUNDS

GHRH analog (with or without DAC)

NOT MEDICAL ADVICE

This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.

Onpeps

Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.

EXPLORE

Home Peptide Library About Blog Peptide Vendors Research Tools Brand Kit

Instagram LinkedIn Spotify

Ipamorelin

Peptide intelligence, every Monday.